Alethio Therapeutics Raises €80.46M Series A for Blood Cancer Drugs

Oxford spin-out Alethio Therapeutics closed an oversubscribed €80.46M Series A led by Sofinnova Partners and RA Capital to advance antibody ATX-011 into the clinic.